Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Cencora (COR) , which belongs to the Zacks Medical Services industry. This prescription drug distributor has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 4.57%. For the most recent quarter, Cencora was expected to post earnings of $ ...

Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 10.3% year to date compared with the industry's 7.4% growth. The S&P 500 Index has risen 17.7% in the same time frame. Cencora is one of the world's largest pharmaceutical service companies, focused on providing drug distribution and related services to reduce healthcare costs and improve ...

It has been about a month since the last earnings report for Cencora (COR) . Shares have lost about 2.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Cencora due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Cencora Q3 Earnings Beat Estimates,'24 View Raised C ...

Cencora, Inc. (COR) witnessed strong momentum in the year-to-date period. Shares of the company have rallied 16.6% compared with 6% growth of the industry. The S&P 500 Composite has risen 17.5% during the same time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Chesterbrook, PA-based Cencora is one of the world's largest pharmaceutical services companies, which focuses on providing drug ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? Developed alo ...

Cencora (COR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. Since a chan ...

Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $1.1 ... [+] billion, which will be used "primarily for debt paydown and general corporate purposes," the drugstore giant said August 1, 2024 In this photo, a business sign hangs over the entrance to a Walgreens pharmacy and store in Alexandria, Virginia. (Photo by Robert Alexander/Getty Images) Getty Images Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $1.1 billi ...

Cencora (COR) reported $74.24 billion in revenue for the quarter ended June 2024, representing a year-overyear increase of 10.9%. EPS of $3.34 for the same period compares to $2.92 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $73.58 billion, representing a surprise of +0.90%. The company delivered an EPS surprise of +5.03%, with the consensus EPS estimate being $3.18. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |-------------------------------------------------------|------------------------------------------------------------------|--------------------------------- ...